The Food and Drug Administration has recently approved the first rapid blood test for methicillin-resistant Staphylococcus aureus.
The test, which is called the BD GeneOhm Staph SR, can detect both methicillin-resistant S. aureus (MRSA) and more common and less dangerous strains of the staph bacterium in just 2 hours.
Manufactured by BD Diagnostics, a subsidiary of BD of Franklin Lakes, N.J., the test uses polymerase chain reaction techniques to detect a gene sequence that is unique to the drug-resistant strain of S. aureus. Traditional microbiology-based cultures require 2472 hours to return results.
In 2005, BD received approval for a similar test, the BD GeneOhm MRSA Assay, which can detect MRSA in nasal specimens. That test is used primarily to screen for the presence of asymptomatic MRSA in patients who are about to enter the hospital so that preventive measures can be taken.
The new blood test will be used primarily to choose among treatment options for patients who are already suspected of having an invasive staph infection.
According to BD spokesperson Barbara Kalavik, the company plans to begin marketing the BD GeneOhm Staph SR as soon as next week in the United States. Marketing began in Europe in late December 2007.
Both versions of the test require the use of a specialized instrument, called a PCR-thermocycler, which costs about $35,000. Not counting the capital cost of this equipment, the new BD GeneOhm Staph SR blood test is expected to cost about $35 per patient, compared with about $25 for the older BD GeneOhm MRSA Assay.
The approval was based on the results of a multicenter clinical trial that demonstrated that the BD GeneOhm Staph SR correctly identified 100% of the MRSA-positive specimens and more than 98% of other staph infections.
According to the FDA statement, "in order to preserve the integrity of positive test results, this test should be used only in patients suspected of a staph infection. The test should not be used to monitor treatment for staph infections because it cannot quantify a patient's response to treatment."
In addition, the FDA warned that the test results should not be used as the sole basis for diagnosis, since positive results may reflect the bacteria's presence in patients who have already been successfully treated for staph infections.
Furthermore, the agency cautioned, the test will not rule out other complicating conditions or infections.